Biosimilar developers are queueing up to file copycat versions of AbbVie's Humira, the world's best-selling drug, and now, another candidate has late…

Pressure is building in Japan for an out-of-cycle reduction in the price of Ono's cancer drug Opdivo.

Celltrion has new data in hand from a Phase III trial of its Rituxan biosimilar CT-P10, putting it in pole position to grab a piece of the brand's $7.39…

South Korean authorities are investigating allegations of insider trading ahead of Boehringer Ingelheim's decision to hand back hot-potato rights to a…

Merck’s Keytruda could become a national tourist attraction in China, with a special approval for imports to the resort island of Hainan.

With forced price cuts for brands such as Gilead Sciences' hep C med Sovaldi already under its belt, the Japanese government is weighing others to help…

Hepatitis C is a big problem in China, and drugmakers are still waiting on approval for their next-gen treatments. Now, regulators are promising action--and…

Pharma companies are risking the wrath of India's drugs regulator by ignoring a demand for clinical trials of combination drugs.

Government warns drugmakers could leave the UK if the country's separation from the EU drags on and is kept under wraps.

Regulatory